Latest publications

AdnaTest ProstateCancerPanel AR-V7

  • Horie S. et al. (2020)
    Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer. PLOS ONE
  • Vlaeminck-Guillem V. et al. (2019)
    Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients. European Urology Oncology
  • Cappelletti V. et al. (2019)
    Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. Cancers
  • Clark E. et al. (2019)
    Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ
  • Antonarakis E. et al. (2019)
    Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. J Clin Oncol
  • Hench I. et al. (2019)
    Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial). Cancers
  • Zhang T. et al. (2019)
    The Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. ScienceDirect 
  • Josefsson A. et al. (2018)
    Circulating tumor cells mirror bone metastatic phenotype in prostate cancer. Oncotarget